Odronextamab for early follicular lymphoma without prior treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grade 1, 2, or 3A) that tests positive for CD20 (a protein on the cancer cells).
- Your lymphoma is not causing big symptoms and does not have high tumor volume (no nodes over 7 cm, no major symptoms).
- You have not had any previous treatment for lymphoma, including rituximab or other drugs.
- You are 18 or older and have a life expectancy of more than 2 years.
- Your blood counts and organ function (like heart, liver, kidneys) are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This study tests a new combination of two drugs (mosunetuzumab and lenalidomide) compared to standard chemo-immunotherapy for people with newly diagnosed follicular lymphoma that needs treatment. It aims to see if the new combination works better and has fewer side effects.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.